Coronis Neurosciences

Company Overview

Snapshot

Founded in January 2014, Coronis Neurosciences operated with 1–10 employees. The company received FDA Orphan Drug Status for Davunetide in February 2018, a significant milestone in its therapeutic development.

Business overview

Coronis Neurosciences was a specialty pharmaceutical company focused on developing therapies for neurocognitive and neurodegenerative disorders. The company's pipeline included CP201, a trans-nasally delivered peptide (NAP) for ADNP syndrome, a rare neurogenetic disease, and CP101, a drug targeting cognitive impairment associated with schizophrenia (CIAS). Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology, Coronis Neurosciences aimed to build value through the clinical development of proprietary formulated drugs for patients.

Strategic signal

In February 2018, Coronis Neurosciences received FDA Orphan Drug Status for Davunetide. This designation is a critical regulatory validation for the company's therapeutic pipeline, indicating recognition of the drug's potential to treat rare diseases and offering development incentives. This signal would have been important for investors, highlighting the company's progress in advancing its drug candidates through regulatory pathways and addressing unmet medical needs.

Company Intelligence Q&A

What was the primary focus of Coronis Neurosciences?

Coronis Neurosciences focused on the development of therapies for neurocognitive and neurodegenerative disorders, including ADNP syndrome and cognitive impairment associated with schizophrenia (CIAS).

What was a key drug candidate in Coronis Neurosciences' pipeline?

CP201 was a leading drug candidate, developed as a trans-nasally delivered peptide (NAP) for the treatment of ADNP syndrome in children.

Did Coronis Neurosciences receive any significant regulatory designations for its drugs?

Yes, in February 2018, Coronis Neurosciences received FDA Orphan Drug Status for Davunetide.

What was the operational status of Coronis Neurosciences?

Coronis Neurosciences ceased to operate in May 2022.